Long term endocrine therapy is frequently related to upregulation of receptor tyrosine kinases (RTKs) such as EGFR and HER2 as well as the activation of ER to promote endocrine resistant tumor cell proliferation [6], but details of mechanisms of activation of RTKs and ER were not yet clear. The gene discussed is ESR1; the disease is neoplasm.